Wegovy Cuts Heart Risk and Reduces Frailty Regardless of How Frail Patients Already Are
A secondary analysis of the SELECT trial finds semaglutide reduces cardiovascular events and improves frailty markers even in the most frail patients.
Summary
A new analysis of the large SELECT trial shows that semaglutide (Wegovy) reduces major cardiovascular events — heart attack, stroke, and cardiovascular death — equally well across all levels of frailty in adults with heart disease and obesity. Importantly, the most frail participants actually gained more quality-of-life benefit than healthier patients, with improvements in mobility and self-care. They were also less likely to stop the medication due to side effects. On top of that, semaglutide made it more likely that patients would improve their frailty category over two years and less likely that they would worsen. These findings challenge the common clinical habit of under-treating frail older adults with effective medications out of safety concerns.
Detailed Summary
Frailty is one of the most powerful predictors of poor health outcomes in older adults, yet frail patients are routinely denied effective medications because clinicians worry the benefits won't outweigh the risks. A post-hoc analysis of the SELECT trial, published in JAMA Cardiology, directly challenges that assumption for semaglutide (Wegovy).
The SELECT trial enrolled adults with established cardiovascular disease and overweight or obesity. This secondary analysis stratified participants by baseline frailty — defined as accumulated age-related deficits — and examined whether frailty modified semaglutide's effects. At 104 weeks, the drug's reduction in the primary composite outcome of cardiovascular death, nonfatal heart attack, and nonfatal stroke was consistent across all frailty categories, with no statistically significant interaction. Results held when frailty was modeled as a continuous variable.
Beyond the primary cardiovascular outcome, semaglutide also reduced composite heart failure events, all-cause hospitalization, and all-cause mortality without any meaningful difference by frailty level. Crucially, the most frail participants experienced significantly greater improvements in health-related quality of life — measured by the EuroQol 5-Dimension index — largely driven by gains in mobility, self-care, and ability to perform usual activities. They were also less likely to discontinue treatment due to adverse events compared with placebo.
Perhaps the most striking finding was that semaglutide users were more than twice as likely to shift into a less frail category (OR 2.46) and roughly half as likely to worsen in frailty (OR 0.47). This suggests obesity management may directly slow or partially reverse frailty progression — a meaningful insight for aging populations.
As a post-hoc analysis, causal conclusions are limited. Frailty measurement relied on accumulated deficit indices rather than gold-standard physical assessments. Independent replication in trials designed specifically around frail older adults will be needed before these findings fully reshape clinical guidelines.
Key Findings
- Semaglutide reduced major cardiovascular events equally across all frailty levels with no significant interaction detected.
- Frail patients on semaglutide gained significantly more quality-of-life improvement than non-frail patients.
- Semaglutide users were 2.46 times more likely to improve their frailty category over two years.
- The most frail participants were less likely to discontinue semaglutide due to adverse events than placebo controls.
- All-cause mortality, heart failure, and hospitalization reductions were consistent regardless of baseline frailty.
Methodology
This is a news report summarizing a post-hoc secondary analysis of the SELECT randomized controlled trial, published in JAMA Cardiology — a high-credibility peer-reviewed journal. The evidence basis is a large, pre-existing RCT dataset; however, post-hoc subgroup analyses are hypothesis-generating rather than confirmatory.
Study Limitations
As a post-hoc analysis, findings cannot establish causality and may be subject to multiple-testing concerns. Frailty was measured via accumulated deficit indices rather than direct physical performance assessments such as grip strength or gait speed. Prospective trials specifically designed to enroll frail older adults are needed to confirm these results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: